Evidence map›Paper›PMID 28725048›Full record

ArticleScientific reports2017

CD300f:IL-5 cross-talk inhibits adipose tissue eosinophil homing and subsequent IL-4 production.

Perri Rozenberg, Hadar Reichman, Israel Zab-Bar, Michal Itan, Metsada Pasmanik-Chor, Carine Bouffi, Udi Qimron, Ido Bachelet, Patricia C Fulkerson, Marc E Rothenberg and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 28 citations in OpenAlex.

  1. Dynamic regulation of CD300b and CD300f on myeloid cells in oral immunotherapy.The journal of allergy and clinical immunology. Global · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Perri RozenbergDepartment of Clinical Microbiology and Immunology, The Sackler School of Medicine, Tel-Aviv University, Ramat Aviv, 69978, Israel.
Hadar ReichmanDepartment of Clinical Microbiology and Immunology, The Sackler School of Medicine, Tel-Aviv University, Ramat Aviv, 69978, Israel.
Israel Zab-BarDepartment of Clinical Microbiology and Immunology, The Sackler School of Medicine, Tel-Aviv University, Ramat Aviv, 69978, Israel.
Michal ItanDepartment of Clinical Microbiology and Immunology, The Sackler School of Medicine, Tel-Aviv University, Ramat Aviv, 69978, Israel.
Metsada Pasmanik-ChorBioinformatics Unit, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, 64239, Israel.
Carine BouffiDivision of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
Udi QimronDepartment of Clinical Microbiology and Immunology, The Sackler School of Medicine, Tel-Aviv University, Ramat Aviv, 69978, Israel.ORCID 0000-0003-2169-5270
Ido BacheletAugmanity Nano LTD, Rehovot, Israel.
Patricia C FulkersonDivision of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
Marc E RothenbergDivision of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
Ariel MunitzDepartment of Clinical Microbiology and Immunology, The Sackler School of Medicine, Tel-Aviv University, Ramat Aviv, 69978, Israel. arielm@post.tau.ac.il.
Tel Aviv University · ILCincinnati Children's Hospital Medical Center · USAugmanity Nano Ltd. (Israel)

Funding

Stem Cell/Organoid and Genome Editing CoreP30DK078392 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI Alexander Miethke · 2007 to 2026
$24.4M
Regulation of Gastrointestinal EosinophilsR37AI045898 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI ROTHENBERG, MARC E. · 2010 to 2019
$3.6M
NIAID NIH HHS R37 AI045898NIDDK NIH HHS P30 DK078392
6 · The paper itself

Abstract

Eosinophils and their associated cytokines IL-4 and IL-5 are emerging as central orchestrators of the immune-metabolic axis. Herein, we demonstrate that cross-talk between the Ig-superfamily receptor CD300f and IL-5 is a key checkpoint that modifies the ability of eosinophils to regulate metabolic outcomes. Generation of Il5

Indexed as

Adipose TissueAnimalsEndothelial CellsEosinophilsExtracellular Signal-Regulated MAP KinasesGlucose IntoleranceInterleukin-4Interleukin-5LigandsMacrophagesMice, Inbred C57BLMice, TransgenicPhosphorylationProto-Oncogene Proteins c-aktReceptors, ImmunologicReceptors, Interleukin-5CLM-1 protein, mouseExtracellular Signal-Regulated MAP KinasesInterleukin-4Interleukin-5LigandsProto-Oncogene Proteins c-aktReceptors, ImmunologicReceptors, Interleukin-5

Identifiers

PMID28725048
PMCPMC5517555
OpenAlexW2734762411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.